Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry-Reference-Cited by-同舟云学术

Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

Published:2024-01 Issue: Volume:17 Page:
ISSN:1756-2848
Container-title:Therapeutic Advances in Gastroenterology
language:en
Short-container-title:Therap Adv Gastroenterol

Author:

Calafat Margalida¹²^ORCID,Torres Paola¹,Tosca-Cuquerella Joan³,Sánchez-Aldehuelo Rubén⁴,Rivero Montserrat⁵⁶,Iborra Marisa⁷,González-Vivo María⁸,Vera Isabel⁹,de Castro Luisa¹⁰,Bujanda Luis¹¹¹²²,Barreiro-de Acosta Manuel¹³,González-Muñoza Carlos¹⁴,Calvet Xavier¹⁵²^ORCID,Benítez José Manuel¹⁶¹⁷,Llorente-Barrio Mónica¹⁸,Surís Gerard¹⁹,Cañete Fiorella¹²,Arias-García Lara²⁰,Monfort David²¹,Castaño-García Andrés²²,Garcia-Alonso Francisco Javier²³,Huguet José M.²⁴,Marín-Jímenez Ignacio²⁵,Lorente Rufo²⁶,Martín-Cardona Albert²⁷²,Ferrer Juan Ángel²⁸,Camo Patricia²⁹,Gisbert Javier P.³⁰²^ORCID,Pajares Ramón³¹,Gomollón Fernando³²²,Castro-Poceiro Jesús³³,Morales-Alvarado Jair³⁴,Llaó Jordina³⁵,Rodríguez Andrés³⁶,Rodríguez Cristina³⁷,Pérez-Galindo Pablo³⁸,Navarro Mercè³⁹,Jiménez-García Nuria⁴⁰,Carrillo-Palau Marta⁴¹,Blázquez-Gómez Isabel⁴²,Sesé Eva⁴³,Almela Pedro⁴⁴,Ramírez de la Piscina Patricia⁴⁵,Taxonera Carlos⁴⁶^ORCID,Rodríguez-Lago Iago⁴⁷,Cabrinety Lidia⁴⁸,Vela Milagros⁴⁹,Mínguez Miguel³,Mesonero Francisco⁴^ORCID,García María José⁵⁶^ORCID,Aguas Mariam⁷,Márquez Lucía⁸,Silva Porto Marisol⁹,Pineda Juan R.¹⁰,García-Etxebarría Koldo¹¹¹²²^ORCID,Bertoletti Federico¹⁴,Brunet Eduard¹⁵²,Mañosa Míriam¹²,Domènech Eugeni⁵⁰⁵¹²

Affiliation:

1. Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain

3. Gastroenterology Department, Hospital Clínic Universitari de València, València, Spain

4. Gastroenterology Department, Hospital Ramón y Cajal, Madrid Spain

5. Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

6. Instituto de investigación IDIVAL, Santander, Spain

7. Gastroenterology Department, Hospital Universitari i Politècnic La Fe, València, Spain

8. Gastroenterology Department, Hospital del Mar, Barcelona, Spain

9. Gastroenterology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

10. Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain

11. Biodonostia Health Research Institute, San Sebastián, Spain

12. Universidad del País Vasco/Euskal Herriko Unibertsitatea, San Sebastián, Spain

13. Gastroenterology Department, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

14. Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

15. Gastroenterology Department, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain

16. Gastroenterology Department, Hospital Universitario Reina Sofía, Córdoba, Spain

17. Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain

18. Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain

19. Gastroenterology Department, Hospital Universitari de Bellvitge (L’ Hospitalet de Llobregat), Barcelona, Spain

20. Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain

21. Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain

22. Gastroenterology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

23. Gastroenterology Department, Hospital Universitario Río Hortega, Valladolid, Spain

24. Gastroenterology Department, Hospital General Universitari de València, València, Spain

25. Gastroenterology Department, Hospital Gregorio Marañón, Madrid, Spain

26. Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

27. Gastroenterology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain

28. Gastroenterology Department, Hospital Universitario Fundación de Alcorcón (Madrid), Spain

29. Gastroenterology Department, Hospital General San Jorge, Huesca, Spain

30. Gastroenterology Department, Hospital Universitario de La Princesa, IIS Princesa and UAM, Madrid, Spain

31. Gastroenterology Department, Hospital Universitario Infanta Sofía, Madrid, Spain

32. Gastroenterology Department, Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Zaragoza, Spain

33. Gastroenterology Department, Hospital Clínic de Barcelona, Barcelona, Spain

34. Gastroenterology Department, Hospital General de Granollers, Granollers, Spain

35. Gastroenterology Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain

36. Gastroenterology Department, Hospital General Universitari d’Alacant, Alacant, Spain

37. Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain

38. Gastroenterology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

39. Gastroenterology Department, Hospital Moisès Broggi, Sant Joan Despí, Spain

40. Gastroenterology Department, Hospital General Universitari d’Elx, Elx, Spain

41. Gastroenterology Department, Hospital Universitario de Canarias, La Laguna, Spain

42. Gastroenterology Department, Hospital Universitario de Torrejón, Torrejón, Spain

43. Gastroenterology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain

44. Gastroenterology Department, Hospital General Universitari de Castelló, Castellón, Spain

45. Gastroenterology Department, Hospital Universitario de Álava, Vitoria, Spain

46. Gastroenterology Department, Hospital Clínico San Carlos, Madrid, Spain

47. Gastroenterology Department, Hospital Universitario de Galdakao, Biocruces Bizkaia HRI, Galdakao, Spain

48. Gastroenterology Department, Hospital Universitari Joan XXIII, Tarragona, Spain

49. Gastroenterology Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

50. Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, Catalonia 08916, Spain

51. Departament de Medicina, Universitat Autònoma de Barcelona

Abstract

Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.

Funder

AbbVie

Pfizer

Galápagos

Janssen Pharmaceuticals

Biogen

Takeda Pharmaceutical Company

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/17562848231221713

Reference25 articles.

1. An Overview of the Natural History of Inflammatory Bowel Diseases

2. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

3. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis

4. Long-term outcome after infliximab for refractory ulcerative colitis

5. Systematic review: infliximab therapy in ulcerative colitis